Please login to the form below

Not currently logged in
Email:
Password:

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

BrainBiogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).

The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.

The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.

Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.

“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”

Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.

Article by
Gemma Jones

11th August 2017

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics